Ivanova Saška, Zorzano Antonio
Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Barcelona, Spain.
Mol Cell Oncol. 2019 Jun 24;6(5):e1632687. doi: 10.1080/23723556.2019.1632687. eCollection 2019.
The binding of ligands to death receptors elicits distinct outcomes, such as apoptosis, inflammation and necroptosis, depending on the cellular context. We have recently described that the autophagic protein TP53INP2 favors apoptosis upon death receptor signaling and is a potential biomarker of responsiveness to TRAIL treatment.
配体与死亡受体的结合会引发不同的结果,如细胞凋亡、炎症和坏死性凋亡,这取决于细胞环境。我们最近发现,自噬蛋白TP53INP2在死亡受体信号传导时有利于细胞凋亡,并且是对TRAIL治疗反应性的潜在生物标志物。